Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases: 3-year follow-up results from the phase 2 PERMEATE trial.

Authors

null

Min Yan

Department of Breast Disease, Henan Breast Cancer Center. The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China

Min Yan , Quchang Ouyang , Tao Sun , Limin Niu , Jin Yang , Li Li , Yuhua Song , Chunfang Hao , Zhanhong Chen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

HER2-Positive

Clinical Trial Registration Number

NCT03691051

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 1048)

DOI

10.1200/JCO.2023.41.16_suppl.1048

Abstract #

1048

Poster Bd #

269

Abstract Disclosures